The Transitional Coverage for Emerging Technologies Pathway will expedite the coverage of certain FDA-designated breakthrough devices, according to an Aug. 8 news release from the agency.
Each year, CMS will accept up to five TCET candidates and aims to finalize a national coverage determination within six months of a device’s FDA market authorization.
The TCET pathway is voluntary and will incorporate evidence preview and development planning stages, allowing manufacturers to address evidence gaps through fit-for-purpose studies tailored to the Medicare population. The pathway will also help determine the device’s appropriate Medicare benefit category, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
